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Physiologic turnover of interstitial collagen is medi-
ated by a sequential pathway in which collagen is
fragmented by pericellular collagenases, endocy-
tosedby collagen receptors, and routed to lysosomes
for degradation by cathepsins. Here, we use intravital
microscopy to investigate if malignant tumors, which
are characterized by high rates of extracellular
matrix turnover, utilize a similar collagen degradation
pathway. Tumors of epithelial, mesenchymal, or neu-
ral crest origin all display vigorous endocytic collagen
degradation. The cells engaged in this process are
identified as tumor-associated macrophage (TAM)-
like cells that degrade collagen in a mannose recep-
tor-dependent manner. Accordingly, mannose-re-
ceptor-deficient mice display increased intratumoral
collagen. Whole-transcriptome profiling uncovers a
distinct extracellular matrix-catabolic signature of
these collagen-degrading TAMs. Lineage-ablation
studies reveal that collagen-degrading TAMs origi-
nate from circulating CCR2+ monocytes. This study
identifies a function of TAMs in altering the tumor
microenvironment through endocytic collagen turn-
over and establishes macrophages as centrally
engaged in tumor-associated collagen degradation.INTRODUCTION
Invasive tumor growth causes loss of tissue architecture and
organ failure (Danø et al., 1985; Liotta et al., 1983; Sloane and
Honn, 1984). It involves extensive degradation of interstitial3662 Cell Reports 21, 3662–3671, December 26, 2017
This is an open access article under the CC BY-NC-ND license (http://collagen, which is the most abundant extracellular matrix
(ECM) component. ECM degradation allows for physical expan-
sion and facilitates tumor growth by growth factor release from
the ECM (Hynes, 2009). ECM degradation is often accompanied
by deposition of a tumor-supporting ECM with altered stiffness,
composition, and organization (Kaukonen et al., 2016; Lu et al.,
2012; Naba et al., 2014; Schedin and Keely, 2011). Interstitial
collagen is a dense network of collagen fibers stabilized by
multiple inter- and intramolecular crosslinks (Linsenmayer,
1991; Ricard-Blum and Ville, 1989), forming a supramolecular
structure refractory to all but a handful of proteolytic enzymes
of the matrix metalloproteinase (MMP) family. These collage-
nases cleave collagen at a single site (Aimes and Quigley,
1995; Birkedal-Hansen, 1987; Freije et al., 1994; Hasty et al.,
1987; Hotary et al., 2000, 2006; Kna¨uper et al., 1996; Netzel-Ar-
nett et al., 2002; Stricklin et al., 1977) to release large collagen
fragments that are internalized through the engagement of endo-
cytic receptors of the mannose receptor (MR) family and
collagen-binding b1 integrins. The internalized collagen frag-
ments are routed to lysosomes and degraded by lysosomal ca-
thepsins (Engelholm et al., 2003; Everts et al., 1985; Everts and
Beertsen, 1992; Kjøller et al., 2004; Lee et al., 1996, 2006;
Madsen et al., 2007, 2011, 2012, 2013; Martinez-Pomares
et al., 2006).
Tumor-associated macrophages (TAMs) are the most abun-
dant leukocytes in tumor stroma. TAMs derive from tissue-resi-
dent macrophages or from recruited inflammatory monocytes
conditioned by the tumor microenvironment (Franklin et al.,
2014; Lahmar et al., 2016; Noy and Pollard, 2014), and the
density of TAMs correlates with prognosis (Biswas et al., 2013;
Zhang et al., 2012).
We recently established an imaging assay that enables the
visualization of cellular collagen degradation in situ (Madsen
et al., 2013). Here, we used this assay to study endocytic turn-
over of interstitial collagen in the tumor microenvironment ofcreativecommons.org/licenses/by-nc-nd/4.0/).
syngrafted and genetically induced mouse cancers. Irrespective
of tumor type, endocytic interstitial collagen turnover was
vigorous and mediated by cells phenotypically resembling
TAMs. The cells expressed high levels of M2 markers and
depended on the MR for endocytic collagen degradation. Tran-
scriptomic profiling of fluorescence-activated cell sorting
(FACS)-isolated collagen-endocytosing TAMs revealed a
distinct ECM-catabolic signature, characterized by high expres-
sion of ECM-degrading enzymes and low expression of ECM
proteins. Collagen-endocytosing TAMs mostly were derived
from CCR2+ inflammatory monocytes recruited to the tumor
microenvironment. The study establishes TAMs as mediators
of tumor-associated endocytic collagen degradation.
RESULTS
Endocytic Pathway for Collagen Turnover Is Highly
Active in Solid Tumors
Acid-extracted fluorescence-labeled rat-tail collagen fibrils
spontaneously form collagen fiber networks when placed in
connective tissue. The fate of this collagen can be followed by
two-photon or confocal microscopy (Madsen et al., 2013). We
injected fluorescent collagen and dextran, a lysosomal marker,
into subcutaneous Lewis lung carcinoma (LLC) growing in
syngeneic mice and, separately, into adjacent dermis. The
mice carried a Col1a1-GFP transgene allowing for identification
of cancer-associated and dermal fibroblasts. Multiple cells
endocytosing collagen were seen in the tumors 24 hr after
collagen injection, showing that the endocytic collagen degrada-
tion pathway is operative within the tumor microenvironment
(Figure 1A). These collagen-endocytosing cells also endocy-
tosed large amounts of dextran and were not fibroblasts, as
determined by their lack of GFP expression (Figure 1A).
Serial z stack analysis showed that collagen-endocytosing
cells were far more abundant in tumor tissue than in adjacent
dermis (Figures 1A and 1B, quantified in Figure 1C). This is
consistent with the high rate of collagen turnover in neoplastic
tissue, as compared to normal tissue (Jones and De Clerck,
1982; Lu et al., 2012). High-level collagen- and dextran-endocy-
tosing cells were also abundant in syngeneic B16BL6melanoma
of neural crest origin (Figure S1A) and T241 fibrosarcoma of
mesenchymal origin (Figure S1B), as well as in MMTV-PymT
transgene-induced mammary adenocarcinomas (Figure S1C).
In all tumors, collagen-endocytosing cells had identical
morphology and were not tumor-associated fibroblasts, as
shown by the lack of GFP expression (Figures 1A and
S1A–S1C). Taken together, this shows that the endocytic
collagen degradation pathway is highly active in solid tumors,
regardless of tumor cell origin, and that it is executed by a tumor
microenvironment-abundant population of cells different from
tumor-associated fibroblasts.
Macrophages Mediate Endocytic Collagen Degradation
in Tumors
To identify cells mediating endocytic collagen degradation, we
made LLC cells stably expressing dTomato fluorescent protein,
and formed tumors in syngeneic Col1a1-GFP mice, to simulta-
neously visualize tumor cells and tumor-associated fibroblasts.Surprisingly, when tumors were imaged 24 hr after collagen
injection, high-level collagen endocytosing cells were neither
tumor cells nor tumor-associated fibroblasts (Figure 1D). An
absence of collagen endocytosis by tumor cells and by tumor-
associated fibroblasts was also observed when the experiment
was performed using dTomato-expressing T241 fibrosarcoma
cells (Figure 1E). Aligned with this, collagen-endocytosing cells
expressed the macrophage marker CD11b and the M2-macro-
phage marker, MR, as shown by in situ immunostaining of LLC
tumors (Figures 1F and 1G), indicating that collagen-endocytos-
ing cells are TAMs.
To extend these findings, we analyzed single-cell suspensions
from subcutaneous LLC injected with fluorescent collagen and
dextran by flow cytometry (Figures 1H–1K). Consistent with the
in situ immunostaining, most collagen- and dextran-internalizing
cells expressed the pan-macrophage marker F4/80. Interest-
ingly, these cells also frequently expressed the dendritic cell
markers CD11c and MHCII, which were infrequently expressed
on collagen- and dextran non-endocytosing cells (Figure 1K).
This resemblance of TAMs to dendritic cells is aligned with
recent findings (Lohela et al., 2014).
Collagen-Endocytosing Cells Are M2-like TAMs with a
Distinct Matrix Catabolic Signature
We further characterized cells mediating endocytic collagen
degradation in tumors using markers of macrophage polariza-
tion. For this, we generated subcutaneous LLC, injected fluores-
cent collagen, prepared single-cell suspensions 24 hr later, and
isolated CD45+ and CD11b+ cells endocytosing high levels of
collagen and dextran by FACS (Figure 2A). For comparison, we
FACS-isolated CD45+ and CD11b+ cells not endocytosing
dextran and collagen (Figure 2B). qPCR analysis of collagen-
and dextran-endocytosing cells showed high expression of the
M2-macrophage markers, Mrc1 (encoding MR), Retnla (encod-
ing Fizz1), and Arg1 (encoding arginase) and, correspondingly,
a low expression of the M1-macrophage markerNos2 (encoding
iNOS) (Figure 2C).
TAMs may contribute to both ECM turnover and the construc-
tion of a tumor-specific ECM by secreting ECM components
(Afik et al., 2016). To further define collagen-endocytosing
TAMs, we generated subcutaneous LLC using dTomato fluores-
cent protein-expressing LLC cells in Col1a1-GFP mice, followed
by injection of fluorescent collagen to enable the FACS isolation
of cancer cells, tumor-associated fibroblasts, and collagen-en-
docytosing TAMs (Figures 2D and 2E). Each of these cell
populations, as well as tumor cell suspensions prior to
FACS-isolation, was then profiled by RNA sequencing (RNA-
seq). The full dataset is in Table S1. Principal component anal-
ysis showed clear separation of the three cell types, with the total
tumor sample placed closest to the LLC cells (Figure 2F). RNA-
seq data confirmed the expression of M2-macrophage markers
identified by imaging, flow cytometry, and qRT-PCR and also
verified that the sorted dTomato- and GFP-expressing cells
were indeed cancer cells and fibroblasts, respectively
(Figure S2).
Interestingly, collagen-endocytosing TAMs differed from
TAMs described by Afik et al. by low expression of collagen
genes, including fibril-forming collagens, basement membraneCell Reports 21, 3662–3671, December 26, 2017 3663
Figure 1. Tumors Are Infiltrated by High-Level Collagen-Endocytosing M2-Polarized Macrophages
(A andB) Projections of subcutaneous LLC (A) or adjacent dermal tissue (B) 24 hr after injection of fluorescent collagen and dextran intoCol1a1-GFP reporter mice
expressing GFP in fibroblasts.
(C) Quantification of high-level collagen-endocytosing cells in tumor (red bar, examples in A) or in adjacent dermis (green bar, example in B). n = 3 mice (three
z stacks per mouse). Error bars, SD. *p < 0.01.
(D and E) Tumor tissue 24 hr after injection of fluorescent collagen into dTomato-expressing LLC (D) and dTomato-expressing T241 fibrosarcoma (E). Examples of
high-level collagen endocytosing cells are indicated with arrows in (A), (B), (D), and (E).
(F and G) LLC in situ stained for CD11b (F) or MR (G) 24 hr after collagen and dextran injection. Arrows show high-level collagen-endocytosing cells positive for
CD11b (F) or MR (G).
(H–K) Flow cytometry analysis of single-cell suspensions of an LLC tumor for CD11c expression by collagen- and dextran-endocytosing cells (I) or collagen- and
dextran-non-endocytosing cells (J). (K) Percentages of dextran- and collagen-endocytosing cells (green bars) or dextran- and collagen-non-endocytosing cells
(red bars) from tumor single-cell suspensions positive for the indicated surface markers based on flow cytometry analysis exemplified in (H)–(J). n = 4 mice. Error
bars, SD.collagens, and fibril-associated collagens with interrupted triple
helices, proteoglycans, and other ECM glycoproteins, which
were expressed at much higher levels in tumor-associated fibro-
blasts (Figure 2G). Collagen-endocytosing TAMs expressed high
levels of cathepsins, which is consistent with high lysosomal
degradation capacity (Figure 2H). Collagen-endocytosing
TAMs also expressed the highest levels of the genes encoding3664 Cell Reports 21, 3662–3671, December 26, 2017the collagenases MMP-8, and MMP-13, as well as high levels
of the genes encoding the gelatinase MMP-9 and the elastase
MMP-12. Genes encoding MMP-3 and the collagenases
MMP-2 and MMP-14 were expressed at higher levels in tumor-
associated fibroblasts (Figure 2H). Finally, genes encoding fibri-
nolytic proteins were mostly expressed by either tumor-associ-
ated fibroblasts or the collagen-endocytosing TAMs (Figure 2H).
Figure 2. A Distinct ECM-Catabolic Transcriptomic Signature of Collagen-Endocytosing TAMs
(A and B) Post-sorting flow cytometry analysis of single-cell suspensions of LLC FACS sorted into CD45+;CD11b+ cells endocytosing dextran and collagen (A) or
not endocytosing dextran and collagen (B).
(C) qRT-PCR analysis forM2-polarizationmarkers (green bars) and anM1-polarizationmarker (blue bar). Data were generated by normalizing the expression level
of dextran- and collagen-endocytosing CD45+;CD11b+ cells to dextran- and collagen-non-endocytosing CD45+;CD11b+ cells. n = 3. Error bars, SD.
(legend continued on next page)
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Collagen-Endocytosing TAMs Originate from CCR2+
Monocytes
To determine the origin of collagen-degrading cells in tumors, we
used a mouse strain that expresses the human diphtheria toxin
(DT) receptor under control of the Ccr2 promoter (CCR2-de-
pleter+/0 mice). This strain was crossed toCcr2+/RFP mice, which
carry a RFP reporter gene inserted into the endogenous Ccr2
gene, to generate Ccr2+/RFP;CCR2-depleter+/0 bi-transgenic
mice and Ccr2+/RFP littermates. This allowed for selective deple-
tion of CCR2+ cells from tumors by the administration of DT and
a simultaneous monitoring of depletion efficacy using flow
cytometry. Accordingly, these mice were inoculated with LLC
and treated with DT. Flow cytometry analysis of single-cell sus-
pensions of tumors showed that CCR2+ cells constituted 21%of
all cells in the tumors of DT-treated Ccr2+/RFP mice (Figure 3A),
and that DT-treatment ofCcr2+/RFP;CCR2-depleter+/0 littermates
resulted in near complete ablation of CCR2+ cells (Figure 3B).
Analysis of single-cell suspensions from collagen-injected LLC
tumors growing in DT-treated Ccr2
+/RFP
mice also revealed that
about half of the collagen-endocytosing cells in tumors were
CCR2+ and about half were CCR2- (Figure 3C). As expected,
the CCR2+ collagen-endocytosing cells were essentially absent
in DT-treated Ccr2+/RFP;CCR2-depleter+/0 bi-transgenic mice
(Figure 3D). Interestingly, CCR2 collagen-endocytosing cells
were also highly reduced after the CCR2 expression-dependent
depletion (compare Figures 3C and 3D, quantified in Figure 3E),
suggesting that most collagen-endocytosing CCR2 cells in
tumors are derived from CCR2+ tumor-recruited monocytes.
MR Mediates Endocytic Collagen Degradation by TAMs
In situ immunostaining (Figure 1G) and transcriptomic profiling of
collagen-endocytosing cells (Figure 2C) revealed a high expres-
sion of MR, a key collagen endocytosis receptor (Madsen et al.,
2013; Martinez-Pomares et al., 2006). To determine the role of
MR in endocytic collagen degradation in tumors, we established
subcutaneous LLC in syngeneic wild-type (Mrc1+/+) mice and
MR-deficient (Mrc1/) littermates, and injected fluorescent
collagen into the tumors. Analysis of tumors growing in Mrc1+/+
mice showed numerous cells endocytosing collagen when
analyzed 24 hr later (Figure 4A). In contrast, we found very few
collagen-endocytosing cells in tumors growing inMrc1/ litter-
mates (Figure 4B). To further analyze the role of MR in tumor-
associated collagen degradation, we affinity purified CD45+
cells fromcollagen-injected LLC growing inMrc1+/+ andMrc1/
mice and analyzed the macrophage populations by flow cytom-
etry (Figures 4C and 4D). Consistent with the image analysis, the
fraction of CD45+, CD11b+, and F4/80+ cells endocytosing high
levels of collagen was dramatically reduced by loss of MR (Fig-
ure 4E). In further support of a pivotal role of MR in endocytic
collagen turnover, when CD45+,CD11b+ cells from LLC were
sorted into MR+ and MR cells and cultured with fluorescently(D and E) Flow cytometry dot plots of single-cell suspensions of LLC. Cells were FA
and F4/80+ cells endocytosing fluorescently labeled collagen (E).
(F) Principal component analysis of each biological RNA-seq replicate from total
shown in (D) and (E).
(G and H) Heatmaps of normalized (Z score) RNA-seq read counts of genes enco
and fibrinolytic factors (plasminogen activation system) (H).
3666 Cell Reports 21, 3662–3671, December 26, 2017labeled collagen, MR+ cells endocytosed 11-fold more collagen
than MR cells (Figures 4F and 4G). Next, we followed the
growth of subcutaneous LLC in MR-deficient mice and wild-
type littermates. The tumors grew slightly slower in MR-deficient
mice (Figure 4H), although the difference did not reach statistical
significance. When analyzing the collagen content of the tumors,
we observed a striking 2.7-fold increase in collagen in tumors of
MR-deficient mice (Figures 4I and 4J).
DISCUSSION
Tumors are rapidly expanding pseudo-organs that efficiently
dissolve existing ECM structures. Accordingly, we found that
the endocytic pathway for interstitial collagen degradation is
highly active in tumors of multiple different origins, and in all tu-
mors, was executed by cells with characteristics of TAMs. These
collagen-degrading TAMs largely originated from circulating
CCR2+ monocytes recruited to the tumor microenvironment,
and MR was identified as the principal collagen endocytosis
receptor on these cells.
TAMs are central orchestrators of a diverse array of processes
critical to tumor initiation, propagation, and dissemination.
These include suppression of anti-tumor cytotoxic T cells, pro-
motion of tumor cell growth, motility, invasion, intravasation,
angiogenesis, and ECM deposition (Afik et al., 2016; Gocheva
et al., 2010; Hughes et al., 2015; Lahmar et al., 2016; Lewis
et al., 2016; Noy and Pollard, 2014; De Palma et al., 2005).
Many of these functions are ascribed to the M2-polarization of
TAMs, and therapeutic approaches aimed at driving TAMs
toward M1 polarization have shown promise in mouse models
of cancer (Georgoudaki et al., 2016; Pyonteck et al., 2013).
Recently, it was reported that CCR2+ monocyte-derived
TAMs were involved not only in ECM turnover, but also in the
deposition of a tumor-specific ECM that stimulates tumor
progression (Afik et al., 2016). This included the synthesis of
ECM components, including collagens. In our transcriptomic
comparison of carcinoma cells, fibroblasts, and collagen-endo-
cytosing TAMs from subcutaneous LLC, we, however, observed
very little contribution from TAMs to the generation of a tumor-
specific ECM. Tumor-associated fibroblasts were the dominant
producers of collagen, proteoglycans, and other ECM glycopro-
teins, whereas tumor cells expressed high levels of some proteo-
glycans and a few glycoproteins. Consequently, TAMs may
encompass distinct subpopulations involved in ECM degrada-
tion and synthesis, respectively.
IL-4-inducedM2polarization ofmacrophageswithin the tumor
microenvironment upregulates cysteine cathepsins, which may
function both in the lysosome and as secreted enzymes to
promote ECM turnover (Olson and Joyce, 2015). Our study
shows that collagen-endocytosing TAMs, in addition to high
levels of cathepsins, express a range of ECM-degradingCS sorted into dTomato-expressing LLC cells, GFP-expressing fibroblasts (D),
tumor RNA, isolated LLC cells, fibroblasts, or collagen-endocytosing TAMs as
ding collagens, proteoglycans, and glycoproteins (G) and cathepsins, MMPs,
Figure 3. Collagen-Endocytosing M2-TAMs Originate from CCR2+
Monocytes
(A–D) LLC growing in Ccr2+/RFP (A and C) or Ccr2+/RFP;CCR2-depleter+/0 mice
(B and D) treated with DT during tumor growth. Ccr2+/RFP mice are DT insen-
sitive, whereas DT depletes CCR2+ cells in Ccr2+/RFP;CCR2-depleter+/0 mice.
(A and C) Flow cytometry analysis of single-cell suspensions of LLC from
Ccr2+/RFP mice shows that about 20% of cells in LLC are CCR2+ (A) and the
majority of collagen-endocytosing TAMs (CD45+;CD11b+ cells) are CCR2+
(C). (B andD) Flowcytometry analysis of LLC fromDT-treatedCcr2+/RFP;CCR2-
depleter+/0 bi-transgenicmice demonstrates efficient depletion of CCR2+ cells
(B) and removal of the vast majority of all collagen-endocytosing M2-TAMs (D).
(E) Collagen-endocytosing M2-TAMs (%) in LLC from DT-treated Ccr2+/RFP
mice (red bar, n = 3) orCcr2+/RFP;CCR2-depleter+/0 mice (gray bar, n = 3). Error
bars, SD. *p < 0.01.enzymes, including collagenases and gelatinases. This implies
that endocytic collagen turnover by TAMs may be a cell-autono-
mous process in which each step of the collagen catabolicsequence leading to lysosomal collagen degradation is executed
by the TAMs. However, our assay, as currently configured,
cannot identify the cells executing the initial collagen fragmenta-
tion. It follows that other cellular constituents of the tumor micro-
environment may actively contribute to TAM-mediated endo-
cytic collagen degradation, for example by aiding the initial
collagen fragmentation. In support of this, we found high expres-
sion of the collagenase MMP-2 and its activator (and collage-
nase) MMP-14 in tumor-associated fibroblasts.
High expression of the elastase MMP-12 and components of
the fibrinolytic system by the collagen-endocytosing TAMs
suggests that other prominent constituents of the tumor ECM,
such as elastin and fibrin, also may be degraded by TAMs. The
degradation of such non-collagenous ECM proteins may also
involve endocytosis (Motley et al., 2016).
In conclusion, we show that tumor-associated collagen degra-
dation involves receptor-mediated endocytic uptake and lyso-
somal degradation of collagen by TAMs displaying a distinct
matrix-catabolic signature.
EXPERIMENTAL PROCEDURES
Animal Experiments
Work was done in an American Association for Accreditation of Laboratory
Animal Care (AAALAC)-certified facility with protocols approved by the
National Institute of Dental and Craniofacial Research (NIDCR) Institutional
Animal Care and Use Committee (NIH) or in accordance with institutional
guidelines approved by the Animal Experiments Inspectorate in Denmark
(Finsen Laboratory/BRIC). See the Supplemental Experimental Procedures
for details on animal husbandry and genotyping.
Subcutaneous Tumors
Subcutaneous tumors were generated by injection of syngeneic C57BL/
6-derived tumor cell lines as previously described (Bugge et al., 1997). See
the Supplemental Experimental Procedures for details.
Histology
Tumors were fixed in zinc-buffered formalin for 24 hr, paraffin embedded,
sectioned, and stained with picrosirius red. Two central areas of each tumor
were selected by light microscopy, and images were acquired using polariza-
tion filters. Picrosirius red-positive areas were determined by ImageJ-based
threshold-analysis. Acquisition and image analysis were blinded.
Monocyte Ablation
Mice were inoculated subcutaneously with 5 3 105 LLC cells and received
bi-daily intraperitoneal injections of 50 ng/g body weight DT, starting on the
day of inoculation and continuing until experimental endpoint 11 days later.
Collagen Labeling
Labeling of acid-extracted rat tail tendon type I collagen with fluorescent dyes
was performed by modification of a previously described procedure (Birkedal-
Hansen et al., 2003). See the Supplemental Experimental Procedures for
details.
In Vivo Collagen Endocytosis
Mice were injected intratumorally with 80 mL of 0.4 mg/mL fluorescently
labeled collagen and 0.3 mg/mL tetramethylrhodamine (TMR)-conjugated
or fluorescein isothiocyanate (FITC)-conjugated 10 kDa dextran (Invitrogen)
neutralized immediately before injection using HEPES-buffered PBS.
18–24 hr later, mice were injected intravenously with 150 mL of 4 mg/mL
Hoechst 33342 trihydrochloride trihydrate dye (Invitrogen). Mice were eutha-
nized 4–6 hr later, and tumors were immediately imaged by confocal
microscopy.Cell Reports 21, 3662–3671, December 26, 2017 3667
Figure 4. MR Mediates Collagen Endocytosis by M2-TAMs
(A and B) Images of collagen-injected LLC from Mrc1+/+ mice (A) or Mrc1/ littermates (B).
(C and D) Flow cytometry analysis of collagen endocytosis by CD45+; F4/80+ cells from LLC grown in Mrc1+/+ mice (C) or Mrc1/ littermates (D).
(E) Percentage of CD45+;CD11b+;F4/80+ cells fromMrc1+/+mice (black bar, n = 3) andMrc1/ littermates (gray bar, n = 3) with high collagen endocytosis based
on flow cytometry analyses as exemplified in (C) and (D). Error bars, SD. *p < 0.01.
(F and G) Single-cell suspension of LLC tumors were enriched for CD45+ cells and sorted into CD11b+;MR (red) and CD11b+;MR+ (green) cells. Plastic-
adhered cells were incubated with Alexa 647-labeled collagen and analyzed by flow cytometry (F). Flow cytometry quantification (G). Error bars, SD. **p < 0.001.
(H) Mrc1+/+ mice (blue line) and Mrc1/ littermates (red line) were inoculated subcutaneously with LLC cells, and tumor sizes were measured from the
appearance of the first palpable tumor until the largest tumor had reached the maximal permitted size. Error bars, SEM.
(I) Images from picrosirius red-stained LLC sections fromMrc1+/+ mice (upper panel) orMrc1/ littermates (lower panel) showing collagen fibers. Bars, 50 mm.
(J) Quantification of picrosirius red (PSR)-positive areas of LLC fromMrc1+/+ mice (blue dots) or fromMrc1/ littermates (red dots). Data are individual values for
each tumor, means, and SEM. *p < 0.05. **p < 0.001.
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Confocal Microscopy
Confocal imaging was performed using a confocal microscope (IX81;
Olympus) equipped with a scanning head (FluoView 1000; Olympus). All
images were acquired using a U Plan S Apochromat 603 numerical aperture,
1.2 water-immersion objective. See the Supplemental Experimental Proced-
ures for details.
Quantitation of Cellular Collagen and Dextran Uptake
Four z stacks of 27-mmsectionswere collected for eachmouse, and each stack
was taken from the same depth within the tissue. The total number of cells in
each z stack was determined by counting all nuclei stained with Hoechst
dye. Final values for cell numbers per mouse were the mean of four z stacks.
In Situ Staining
Tumors were fixed for 4 hr in zinc-buffered formalin 24 hr after collagen and
dextran injection. For MR staining, tumors were permeabilized with 1% Triton
X-100 in PBS for 45 min; washed in PBS, 0.5% BSA, and 0.2% Triton X-100
(PBS-BT);blocked inPBS-BTand2%goatserumforR1hr;and incubatedover-
night at 4C with primary antibody in PBS-BT and 2% goat serum at these dilu-
tions: anti-CD11b (Biolegend) 1:200 and rat anti-MR (AbD Serotec) 1:200. Tu-
mors were washed in PBS-BT and incubated overnight at 4C with Alexa Fluor
488-conjugated secondary antibodies diluted at 1:500 inPBS-BT. After washing
in PBS-BT, the tissue was incubated for 1 hr with Hoechst diluted at 1:10,000 in
PBS-BT,washed, and imaged asdescribed in theConfocalMicroscopy section.
FACS and RNA Isolation
Alexa 647-collagen and TMR-dextran were injected into LLC as described
above. Tumors were harvested 24 hr later, and single-cell suspensions were
prepared. Cells were blocked with Fc receptor-blocking reagent and enriched
for CD45+ cells using magnetic anti-CD45 microbeads (Miltenyi). Cells were
stained with Zombie aqua and anti-CD11b antibody (cl. M1/70, Biolegend)
for 1 hr on ice, gated for theZombie aqua-negative andCD11b+cell population,
and sorted into dextran- and collagen-endocytosing cells and dextran- and
collagen-non-endocytosing cells on a FACS Aria II (BD Biosciences). 1 to
23 105 cells of each of the two cell populations were isolated from each sam-
ple. In other experiments, Alexa 647-collagen was injected into dTomato-ex-
pressing LLC growing inCol1a1-GFPmice. 24 hr later, single-cell suspensions
were prepared, Fc receptor blocked, and stained with Zombie aqua and anti-
F4/80 antibody. Cells were sorted into dTomato+ cells (cancer cells), GFP+
cells (fibroblasts), and dTomato-;GFP;F4/80+;collagen+ cells (M2-TAMs).
RNAwas isolated by Trizol (Invitrogen) lysis, phase separation with chloroform,
and purification using a QIAGEN RNA micro purification kit.
qPCR
100 ng total RNA was used for oligo(dT)-mediated first-strand cDNA synthesis
(Superscript III First-Strand Synthesis SuperMix; Invitrogen). Gene expression
analysis was performed in cell populations from 3 individual tumors using the
real-time PCR detection system (iCycler iQ; Bio-Rad Laboratories) and iQ
SYBRGreen Supermix (Bio-Rad Laboratories). Primers are in Table S2. Details
on PCR and data analysis are in the Supplemental Experimental Procedures.
RNA-Seq
RNA quality was assessed by Agilent 2100 Bioanalyzer. Total RNA (200 ng) was
prepared using polydT-mediated cDNA synthesis in accordancewith themanu-
facturer’s (Illumina) instructions. Libraries were made with a NEBNext RNA
Library PreparationKit for Illumina. Library qualitywas assessed usingFragment
Analyzer (AATI), followed by library quantification (Illumina LibraryQuantification
Kit). Sequencingwas done on a HiSeq1500 platform (Illumina) with a read length
of 50 bp. Sequencing depth and alignment information is in Table S3. Details on
data analysis are in the Supplemental Experimental Procedures.
Ex Vivo Collagen Endocytosis
Single-cell suspensions of LLC cells were enriched for CD45+ cells and
stained with Zombie aqua, anti-CD11b (Biolegend), and anti-MR (Biolegend)
antibodies as described above. Cells were sorted into CD11b+;MR+ and
CD11b+;MR cells using a FACS Aria I (BD Biosciences) and plated in
24-well plates (5 to 93 104 cells/well). Alexa 647-labeled collagen was addedovernight at a final concentration of 15 mg/mL. Cells were trypsinized, stained
with Zombie aqua, and analyzed by flow cytometry with a LSRII flow cytometer
(BD Biosciences).
Statistics
Significance was tested by unpaired 2-tailed Student’s t test, assuming
independent variables, normal distribution, and equal variance of samples.
Calculations were made with GraphPad Prism software.
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA-seq data reported in this study is GEO:
GSE107053.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and three tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2017.12.011.
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